Loading people...
David Kabakoff is a Founding Partner at HealthQuest Capital based in San Diego, where he leverages over 44 years of industry experience to invest in biotechnology, pharmaceuticals, and medical diagnostics. During his tenure as a senior executive at Hybritech, he led teams that developed iconic diagnostic products, including the first rapid pregnancy test, the rapid strep throat test, and the PSA test for prostate cancer. He previously served as an Executive Partner at Sofinnova Investments and held chief executive roles at Corvas International, Dura Pharmaceuticals, and Salmedix, which was acquired by Cephalon. Kabakoff currently serves on the boards of multiple portfolio companies, including RareCyte and Castle Biosciences, having previously guided investments like Lineagen and Biotheranostics to successful acquisitions. He holds a BA from Case Western Reserve University and a PhD in Chemistry from Yale University.
David Kabakoff serves as a distinguished Partner at HealthQuest Capital, a leading venture capital firm dedicated to investing in innovative healthcare companies. With a profound understanding of the life sciences landscape, David plays a pivotal role in identifying and nurturing the next generation of healthcare leaders. His work at HealthQuest Capital focuses on early to growth-stage companies that are poised to make a significant impact on patient care and healthcare delivery.
At HealthQuest Capital, David Kabakoff's investment focus spans a broad spectrum of the healthcare industry. He is particularly interested in biotechnology, medical devices, diagnostics, digital health, and healthcare services. David seeks out companies that are developing disruptive technologies and solutions, possess strong intellectual property, and are led by experienced management teams. His investment philosophy is rooted in supporting innovations that address critical unmet medical needs, improve clinical outcomes, and enhance efficiency within the healthcare ecosystem. He is known for his strategic insights and ability to guide portfolio companies through complex development and commercialization phases.
Prior to joining HealthQuest Capital, David Kabakoff built an impressive career with extensive operational and scientific leadership experience in the life sciences sector. He held senior executive positions, including CEO roles, at several successful biotechnology companies. Notably, he served as CEO of Salmedix Inc., a company focused on oncology therapeutics, which was successfully acquired by Cephalon. His earlier career also includes significant contributions at companies like Corvas International, where he was involved in developing novel therapeutics. Throughout his career, David has been instrumental in the development and commercialization of numerous medical products, demonstrating a deep expertise in R&D, clinical development, and corporate strategy. He holds a Ph.D. in Chemistry from Yale University and a B.S. in Chemistry from the University of Miami, providing him with a robust scientific foundation that informs his investment decisions.
David Kabakoff's unique blend of scientific acumen, operational leadership, and investment expertise makes him a valuable asset to HealthQuest Capital and its portfolio companies. His commitment to fostering innovation continues to drive advancements in healthcare, ultimately benefiting patients worldwide.
David Kabakoff is a Partner at HealthQuest Capital, a prominent venture capital firm specializing in healthcare investments. He is an experienced investor and operational leader with a strong background in biotechnology and life sciences.
David Kabakoff invests in innovative healthcare companies, with a particular focus on biotechnology, medical devices, diagnostics, digital health, and healthcare services. He seeks companies addressing significant unmet medical needs.
David Kabakoff works as a Partner at HealthQuest Capital, a leading healthcare-focused venture capital firm.
